Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 2
Submit an article Journal homepage
768
Views
25
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients

Joon Seong ParkDepartment of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea
,
Sung-Eun LeeDepartment of Hematology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea
,
Seong Hyun JeongDepartment of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea
,
Eun-Jung JangDepartment of Hematology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea
,
Mi-Yeon ChoiDepartment of Hematology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea
,
Hyeoung-Joon KimDepartment of Hematology-Oncology, Chonnam National University Hwasun, Hospital, Hwasun, Korea
,
Yeo-Kyeoung KimDepartment of Hematology-Oncology, Chonnam National University Hwasun, Hospital, Hwasun, Korea
,
Sung-Hyun KimDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
,
Dae Young ZangDepartment of Internal Medicine, Hallym University College of Medicine, Anyang, Korea
,
Sukjoong OhDivision of Hematology-Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University, Seoul, Korea
,
Dong Hoe KooDivision of Hematology-Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University, Seoul, Korea
,
Hawk KimDivision of Hematology and Cellular Therapy, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
,
Young Rok DoDivision of Hematology-Oncology, School of Medicine, Keimyung University, Daegu, Korea
,
Jae-Yong KwakDivision of Hematology-Oncology, Chonbuk National University Medical School, Jeonju, Korea
,
Jeong-A KimDepartment of Hematology, St Vincent's Hospital, The Catholic University of Korea, Suwon, Korea
,
Dae-Young KimDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
,
Yeung-Chul MunDepartment of Hematology, School of Medicine, Ewha Womans University, Seoul, Korea
,
Won Sik LeeDepartment of Internal Medicine, Inje University College of Medicine, Inje University Busan Paik Hospital, Busan, Korea
,
Myung Hee ChangDepartment of Hematology-Oncology, National Health Insurance Service Ilsan Hospital, Ilsan, Korea
,
Jinny ParkDepartment of Hematology, Gachon University Gil Hospital, Incheon, Korea
,
Ji Hyun KwonDepartment of Hematology-Oncology, Chungbuk National University Hospital, Cheongju, Korea
&
Dong-Wook KimDepartment of Hematology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, KoreaCorrespondence[email protected]
 show all
Pages 341-347 | Received 09 Feb 2015, Accepted 02 May 2015, Published online: 12 Jun 2015

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Aisling Nee & Jeffrey H. Lipton. (2019) Update on the management of chronic myeloid leukemia: current best practice and future directions. Expert Opinion on Orphan Drugs 7:4, pages 157-169.
Read now
Onur Kirkizlar & Ahmet Emre Eskazan. (2016) Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Expert Review of Quality of Life in Cancer Care 1:5, pages 353-359.
Read now

Articles from other publishers (23)

Jie Luo, Xin Du, Jin Lou, Jianwei Wu, Liping Ma, Jixian Huang, Liangtuo Wang, Chuanqing Tu, Zelin Liu, Liya Chen, Yaxian Tan, Dongmei Luo, Hanyin Liang, Changxin Yin, Rui Cao, Xuan Zhou, Qifa Liu, Xiaoli Liu & Na Xu. (2022) De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China. eJHaem 3:4, pages 1220-1230.
Crossref
Ekaterina Yu. Chelysheva, Anna N. Petrova, Oleg A. Shukhov, Anastasiia V. Bykova, Irina S. Nemchenko, Margarita A. Gurianova, Nikolay N. Tsyba & Anna G. Turkina. (2022) Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia. Terapevticheskii arkhiv 94:7, pages 836-843.
Crossref
Haruko Shima, Akiko Kada, Akihiko Tanizawa, Iori Sato, Chikako Tono, Masaki Ito, Yuki Yuza, Akihiro Watanabe, Kiyoko Kamibeppu, Hideko Uryu, Katsuyoshi Koh, Chihaya Imai, Nao Yoshida, Yuhki Koga, Naoto Fujita, Akiko M. Saito, Souichi Adachi, Eiichi Ishii & Hiroyuki Shimada. (2022) Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia. Pediatric Blood & Cancer 69:8.
Crossref
Fabio EfficacePhDPhD & Michele BaccaraniMDMD. (2022) Quality of Life Improvements in Patients With Chronic Myeloid Leukemia After Stopping Long-Term Therapy: Who Can Benefit the Most?. JNCI: Journal of the National Cancer Institute 114:1, pages 9-11.
Crossref
Kelly L. Schoenbeck & Kathryn E. Flynn. (2021) Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions. Current Hematologic Malignancy Reports 16:6, pages 491-499.
Crossref
Foulon S, Cony-Makhoul P, Guerci-Bresler A, Daban M, Kapso R, Tubert-Bitter P & Bonastre J. (2021) Health state utility and quality of life measures in patients with chronic myeloid leukemia in France. Quality of Life Research 30:7, pages 2021-2032.
Crossref
Cyril Astrugue, Antoine Bénard, Pauline Bosco-Levy, Stéphanie Dulucq, Magali Rouyer, Régis Lassalle, Nathalie Hayes & François-Xavier Mahon. (2021) Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response. Value in Health 24:5, pages 683-690.
Crossref
Ruth Stuckey, Juan Francisco López-Rodríguez, Santiago Sánchez-Sosa, Adrián Segura-Díaz, Nuria Sánchez-Farías, Cristina Bilbao-Sieyro & María Teresa Gómez-Casares. (2020) Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. World Journal of Clinical Oncology 11:12, pages 996-1007.
Crossref
Delphine Rea. (2020) Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?. Hematology 2020:1, pages 243-247.
Crossref
Delphine Rea. (2020) Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?. Blood Advances 4:21, pages 5589-5594.
Crossref
Andrea Petermann-Meyer & Susanne Isfort. (2020) Psychoonkologische Aspekte in der CML-Behandlung. InFo Hämatologie + Onkologie 23:5, pages 14-17.
Crossref
Lando Janssen, Neeltje A. E. Allard, Christiaan G. J. Saris, Jaap Keijer, Maria T. E. Hopman & Silvie Timmers. (2020) Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology. Physiological Reviews 100:2, pages 633-672.
Crossref
Marc G. Berger, Bruno Pereira, Philippe Rousselot, Pascale Cony‐Makhoul, Martine Gardembas, Laurence Legros, Martine Escoffre‐Barbe, Franck‐Emmanuel Nicolini, Sandrine Saugues, Céline Lambert, Delphine Réa, Agnès Guerci‐Bresler, Stéphane Giraudier, Joëlle Guilhot, Susanne Saussele & François‐Xavier Mahon. (2019) Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. British Journal of Haematology 187:3, pages 337-346.
Crossref
A. N. Petrova, E. Yu. Chelysheva & A. G. Turkina. (2019) Treatment-free remission in patients with chronic myeloid leukemia: literature review. Oncohematology 14:3, pages 12-22.
Crossref
Vamsi Kota & Ehab Atallah. (2019) Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. Clinical Lymphoma Myeloma and Leukemia 19:8, pages 480-487.
Crossref
Juan Carlos Hernández-Boluda, Arturo Pereira, Irene Pastor-Galán, Alberto Alvarez-Larrán, Alisa Savchuk, José Manuel Puerta, José María Sánchez-Pina, Rosa Collado, Alvaro Díaz-González, Anna Angona, Miguel Sagüés, Valentín García-Gutiérrez, Concepción Boqué, Santiago Osorio, Rolando Vallansot, Luis Palomera, Arantxa Mendizábal, Luis Felipe Casado, Manuel Pérez-Encinas, Raúl Pérez-López, Francisca Ferrer-Marín, Fermín Sánchez-Guijo, Carmen García, Natalia de las Heras, José Luis López-Lorenzo, Francisco Cervantes & Juan Luis Steegmann. (2018) Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer Journal 8:10.
Crossref
Delphine Rea & Jean-Michel Cayuela. (2017) Treatment-free remission in patients with chronic myeloid leukemia. International Journal of Hematology 108:4, pages 355-364.
Crossref
Giuseppe Saglio, Giora Sharf, Antonio Almeida, Andrija Bogdanovic, Felice Bombaci, Jelena Čugurović, Nigel Deekes, Valentín Garcia-Gutiérrez, Jan de Jong, Šarūnas Narbutas, Peter Westerweel & Daniela Zackova. (2018) Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective. Clinical Lymphoma Myeloma and Leukemia 18:6, pages 375-379.
Crossref
Stuart L. Goldberg, Michael Savona & Michael J. Mauro. (2018) Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 18:2, pages 98-105.
Crossref
Qian Jiang, Haibo Wang, Lu Yu & Robert Peter Gale. (2017) Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology 143:12, pages 2619-2630.
Crossref
Qian Jiang, Hai-Bo Wang, Lu Yu & Robert Peter Gale. (2017) Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy. Journal of Cancer Research and Clinical Oncology 143:6, pages 1013-1022.
Crossref
Fabio Efficace & Laura Cannella. (2016) The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology 2016:1, pages 170-179.
Crossref
S Saußele, J Richter, A Hochhaus & F-X Mahon. (2016) The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30:8, pages 1638-1647.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.